vs
Side-by-side financial comparison of Cambium Networks Corp (CMBM) and Intellia Therapeutics, Inc. (NTLA). Click either name above to swap in a different company.
Cambium Networks Corp is the larger business by last-quarter revenue ($40.3M vs $23.0M, roughly 1.8× Intellia Therapeutics, Inc.). Cambium Networks Corp runs the higher net margin — -17.9% vs -416.2%, a 398.2% gap on every dollar of revenue. On growth, Intellia Therapeutics, Inc. posted the faster year-over-year revenue change (78.8% vs -23.2%). Cambium Networks Corp produced more free cash flow last quarter ($-10.8M vs $-69.4M). Over the past eight quarters, Intellia Therapeutics, Inc.'s revenue compounded faster (-10.8% CAGR vs -27.2%).
Cambium Networks Corporation is an American manufacturer of wireless telecommunications equipment, including Enterprise WiFi, Network switch, Internet of Things, and fixed wireless broadband and Wi-Fi for enterprises products for Internet access. Publicly traded on the NASDAQ stock exchange, it spun out of Motorola in October 2011.
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineere...
CMBM vs NTLA — Head-to-Head
Income Statement — Q4 FY2024 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $40.3M | $23.0M |
| Net Profit | $-7.2M | $-95.8M |
| Gross Margin | 36.6% | — |
| Operating Margin | -28.4% | -428.9% |
| Net Margin | -17.9% | -416.2% |
| Revenue YoY | -23.2% | 78.8% |
| Net Profit YoY | 71.0% | 25.7% |
| EPS (diluted) | $-0.26 | $-0.81 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $23.0M | ||
| Q3 25 | — | $13.8M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.6M | ||
| Q4 24 | $40.3M | $12.9M | ||
| Q3 24 | $44.7M | $9.1M | ||
| Q2 24 | $45.2M | $7.0M | ||
| Q1 24 | $47.1M | $28.9M |
| Q4 25 | — | $-95.8M | ||
| Q3 25 | — | $-101.3M | ||
| Q2 25 | — | $-101.3M | ||
| Q1 25 | — | $-114.3M | ||
| Q4 24 | $-7.2M | $-128.9M | ||
| Q3 24 | $-34.5M | $-135.7M | ||
| Q2 24 | $-14.2M | $-147.0M | ||
| Q1 24 | $-18.4M | $-107.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 36.6% | — | ||
| Q3 24 | 43.6% | — | ||
| Q2 24 | 32.5% | — | ||
| Q1 24 | 29.8% | — |
| Q4 25 | — | -428.9% | ||
| Q3 25 | — | -808.9% | ||
| Q2 25 | — | -772.2% | ||
| Q1 25 | — | -726.6% | ||
| Q4 24 | -28.4% | -1059.9% | ||
| Q3 24 | -69.6% | -1589.0% | ||
| Q2 24 | -27.2% | -1998.6% | ||
| Q1 24 | -33.1% | -394.0% |
| Q4 25 | — | -416.2% | ||
| Q3 25 | — | -735.2% | ||
| Q2 25 | — | -710.8% | ||
| Q1 25 | — | -687.6% | ||
| Q4 24 | -17.9% | -1001.2% | ||
| Q3 24 | -77.3% | -1489.5% | ||
| Q2 24 | -31.5% | -2112.6% | ||
| Q1 24 | -39.2% | -371.3% |
| Q4 25 | — | $-0.81 | ||
| Q3 25 | — | $-0.92 | ||
| Q2 25 | — | $-0.98 | ||
| Q1 25 | — | $-1.10 | ||
| Q4 24 | $-0.26 | $-1.27 | ||
| Q3 24 | $-1.22 | $-1.34 | ||
| Q2 24 | $-0.51 | $-1.52 | ||
| Q1 24 | $-0.66 | $-1.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $449.9M |
| Total DebtLower is stronger | $67.6M | — |
| Stockholders' EquityBook value | $-3.2M | $671.4M |
| Total Assets | $173.7M | $842.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $449.9M | ||
| Q3 25 | — | $511.0M | ||
| Q2 25 | — | $459.7M | ||
| Q1 25 | — | $503.7M | ||
| Q4 24 | — | $601.5M | ||
| Q3 24 | — | $658.1M | ||
| Q2 24 | — | $691.1M | ||
| Q1 24 | — | $791.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $67.6M | — | ||
| Q3 24 | $67.6M | — | ||
| Q2 24 | $68.9M | — | ||
| Q1 24 | $63.8M | — |
| Q4 25 | — | $671.4M | ||
| Q3 25 | — | $748.4M | ||
| Q2 25 | — | $715.3M | ||
| Q1 25 | — | $779.9M | ||
| Q4 24 | $-3.2M | $872.0M | ||
| Q3 24 | $1.9M | $962.6M | ||
| Q2 24 | $34.1M | $971.1M | ||
| Q1 24 | $45.0M | $1.0B |
| Q4 25 | — | $842.1M | ||
| Q3 25 | — | $925.3M | ||
| Q2 25 | — | $898.9M | ||
| Q1 25 | — | $986.2M | ||
| Q4 24 | $173.7M | $1.2B | ||
| Q3 24 | $194.3M | $1.2B | ||
| Q2 24 | $221.1M | $1.2B | ||
| Q1 24 | $219.8M | $1.3B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 36.12× | — | ||
| Q2 24 | 2.02× | — | ||
| Q1 24 | 1.42× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-10.4M | $-69.3M |
| Free Cash FlowOCF − Capex | $-10.8M | $-69.4M |
| FCF MarginFCF / Revenue | -26.8% | -301.6% |
| Capex IntensityCapex / Revenue | 1.1% | 0.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-21.4M | $-395.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-69.3M | ||
| Q3 25 | — | $-76.9M | ||
| Q2 25 | — | $-99.6M | ||
| Q1 25 | — | $-148.9M | ||
| Q4 24 | $-10.4M | $-85.2M | ||
| Q3 24 | $8.9M | $-84.8M | ||
| Q2 24 | $2.4M | $-58.2M | ||
| Q1 24 | $-15.9M | $-120.7M |
| Q4 25 | — | $-69.4M | ||
| Q3 25 | — | $-76.9M | ||
| Q2 25 | — | $-99.9M | ||
| Q1 25 | — | $-149.7M | ||
| Q4 24 | $-10.8M | $-86.2M | ||
| Q3 24 | $6.8M | $-86.1M | ||
| Q2 24 | $87.0K | $-59.2M | ||
| Q1 24 | $-17.4M | $-123.2M |
| Q4 25 | — | -301.6% | ||
| Q3 25 | — | -558.2% | ||
| Q2 25 | — | -701.0% | ||
| Q1 25 | — | -900.1% | ||
| Q4 24 | -26.8% | -669.4% | ||
| Q3 24 | 15.2% | -945.2% | ||
| Q2 24 | 0.2% | -850.9% | ||
| Q1 24 | -37.0% | -425.7% |
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 0.2% | ||
| Q2 25 | — | 1.7% | ||
| Q1 25 | — | 4.4% | ||
| Q4 24 | 1.1% | 7.6% | ||
| Q3 24 | 4.8% | 14.0% | ||
| Q2 24 | 5.1% | 14.5% | ||
| Q1 24 | 3.3% | 8.7% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CMBM
| Enterprise | $16.6M | 41% |
| Point To Multi Point | $16.4M | 41% |
| Other | $5.8M | 14% |
NTLA
| Avencell Therapeutics Inc | $21.0M | 91% |
| Other | $1.0M | 4% |
| Avencell | $1.0M | 4% |
